Selecta Biosciences, Inc. (SELB) financial statements (2021 and earlier)

Company profile

Business Address 65 GROVE STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13990379784
Cash and cash equivalents13990377159
Short-term investments   2625
Restricted cash and investments 0 00
Receivables75 00
Other undisclosed current assets51522
Total current assets:15197429987
Noncurrent Assets
Operating lease, right-of-use asset110
Property, plant and equipment11222
Restricted cash and investments11000
Other noncurrent assets    0
Other undisclosed noncurrent assets0    
Total noncurrent assets:143222
TOTAL ASSETS:1651004410189
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities91413108
Accounts payable01124
Accrued liabilities8131294
Deferred revenue722
Debt 1921 4
Deferred revenue and credits12
Contract with customer, liability1
Other undisclosed current liabilities1    
Total current liabilities:8235351114
Noncurrent Liabilities
Long-term debt and lease obligation34  218
Long-term debt, excluding current maturities25  218
Operating lease, liability10 
Liabilities, other than long-term debt3915151713
Deferred revenue and credits1613
Deferred revenue3915
Contract with customer, liability14
Deferred rent credit  0
Other liabilities  11 
Other undisclosed noncurrent liabilities2942   
Total noncurrent liabilities:10256153821
Total liabilities:18391504934
Stockholders' equity
Stockholders' equity attributable to parent(18)8(5)5255
Common stock00000
Additional paid in capital391349280273211
Accumulated other comprehensive loss(5)(5)(5)(4)(5)
Accumulated deficit(405)(336)(280)(217)(152)
Receivable from shareholders or affiliates for issuance of capital stock    (0)
Total stockholders' equity:(18)8(5)5255
TOTAL LIABILITIES AND EQUITY:1651004410189

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:177108
Operating expenses(73)(59)(66)(64)(43)
Operating loss:(57)(52)(65)(64)(35)
Nonoperating income (expense)0(1)10(0)
Investment income, nonoperating01110
Foreign currency transaction gain (loss), before tax0(0)0(0)(1)
Other nonoperating income (expense)0(1)0(0)0
Interest and debt expense(2)(2)(1)(2)(1)
Net loss:(58)(54)(65)(65)(36)
Other undisclosed net loss attributable to parent(10)(1)   
Net loss attributable to parent:(69)(55)(65)(65)(36)
Preferred stock dividends and other adjustments    (5)
Net loss available to common stockholders, diluted:(69)(55)(65)(65)(41)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(58)(54)(65)(65)(36)
Other comprehensive income (loss)  (0) 0
Comprehensive loss:(58)(54)(65)(65)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(10)(1) 0 
Comprehensive loss, net of tax, attributable to parent:(69)(55)(65)(65)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: